Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Revita® DMR in patients with insulin-treated type 2 diabetes (T2D). Fractyl’s REVITA-T2Di study is now enrolling in this patient population.
“We are thrilled to work closely with the FDA to accelerate the introduction of a potentially significant therapy for patients with type 2 diabetes who continue to struggle with the burden and risks of their disease,” said Harith Rajagopalan, M.D., Ph.D., co-founder and CEO of Fractyl. “Breakthrough Designation provides recognition from the FDA of the potential value that Revita DMR can bring to patients and an opportunity for accelerated access for patients who need better treatment options.”
The goal of the Breakthrough Device program is to provide patients and health care providers with timely access to certain medical devices that deliver more effective treatment of life-threatening or irreversibly debilitating diseases or conditions by speeding up their development, assessment and review.
Fractyl also announced that the Centers for Medicare and Medicaid Services (CMS) has approved CMS coverage of routine costs for Medicare patients in the REVITA-T2Di trial. All eligible participants will receive study-related health assessments at no cost; this CMS decision allows for reimbursement coverage to clinical research centers for certain trial-related expenses.
Revita DMR (duodenal mucosal resurfacing) is a first-in-class intervention targeting the role of the intestine in metabolic disease. It is an outpatient procedural therapy that uses heat to resurface the lining of the upper intestine, an organ which plays an integral role in metabolic regulation. Fractyl’s preliminary clinical findings suggest that treatment with Revita DMR may decrease insulin resistance, improve glucose control, lower weight and reduce liver fat.
“Type 2 diabetes is not simply a disease of blood sugar, but a multi-organ pathology that leads to progressive pancreatic beta-cell failure, fundamentally caused by insulin resistance. We know that treatment alternatives to current drug therapy are desperately needed to address the type 2 diabetes epidemic,” said Juan Carlos Lopez-Talavera, M.D., Ph.D., Chief Medical Officer of Fractyl. “Providing a therapy that could improve glucose to target range while reducing the need for injectable insulin would be a quantum leap forward for patients. Fractyl is committed to advancing Revita DMR through the clinical and regulatory process to make a potentially meaningful difference in the lives of patients who are affected by this serious, chronic disease.”
Fractyl is now enrolling patients in the REVITA-T2Di trial, which is designed to form the basis for a premarket submission to the FDA in the insulin-treated T2D patient population. The trial is a prospective, randomized, double-blind, sham-controlled study enrolling 300 patients at up to 35 sites around the world. To learn more about the REVITA-T2Di study and enrollment eligibility, visit revitastudy.com.